ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pfizer is paying $295 million for the worldwide rights to Opko Health’s hGH-CTP, a long-acting recombinant human growth hormone analog in Phase III studies as a treatment for growth hormone deficiency in adults. The treatment is also in a Phase II trial in kids. Opko could reap another $275 million in milestone payments for hitting regulatory goals. Opko aims to reduce the dosing of growth hormone from once daily to once weekly. Pfizer says Opko’s treatment will complement its own human growth hormone product, Genotropin, which had $772 million in sales last year.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X